Gene Expression Profiling of Peritoneal Metastases from Appendiceal and Colon Cancer Demonstrates Unique Biologic Signatures and Predicts Patient Outcomes

详细信息	查看全文 | 推荐本文 |

• 作者：Edward A. Levine ; MD ; FACS^a ; ^{elevine@wakehealth.edu} ; Dan G. Blazer III ; MD ; FACS^b ; Mickey K. Kim ; BS^c ; Perry Shen ; MD ; FACS^a ; John H. Stewart IV ; MD ; FACS^a ; Cynthia Guy ; MD^d ; David S. Hsu ; MD ; PhD^c
• 刊名：Journal of the American College of Surgeons
• 出版年：2012
• 期刊代码：175_10727515
• 类别：med
• 出版时间：April, 2012
• 卷：214
• 期：4
• 页码：599-606
• 文件大小：2246 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Background

Treatment of peritoneal metastases from appendiceal and colon cancer with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) shows great promise. Although long-term disease-free survival is achieved in some cases with this procedure, many patients have recurrence. Oncologists have treated such recurrences of appendiceal cancer similarly to colorectal carcinoma, which has been largely ineffective. This study uses gene expression analysis of peritoneal metastases to better understand these neoplasms.

Study Design

From a prospectively maintained database and tissue bank, 41 snap frozen samples of peritoneal metastases (26 appendiceal, 15 colorectal) from patients undergoing HIPEC with complete cytoreduction and more than 3 years of follow-up underwent global gene expression analysis. Distinct phenotypes were identified using unsupervised hierarchical clustering based on differential gene expression. Survival curves restratified by genotype were generated.

Results

Three distinct phenotypes were found, 2 consisting of predominantly low grade appendiceal samples (10 of 13 in Cluster 1 and 15 of 20 in Cluster 2) and 1 consisting of predominantly colorectal samples (7 of 8 in Cluster 3). Cluster 1 consisted of patients with good prognosis and Clusters 2 and 3 consisted of patients with poor prognosis (p = 0.006). Signatures predicted survival of low- (Cluster 1) vs high-risk (Cluster 2) appendiceal (p = 0.04) and low-risk appendiceal (Cluster 1) vs colon primary (Cluster 3) (p = 0.0002).

Conclusions

This study represents the first use of gene expression profiling for appendiceal cancer, and demonstrates genomic signatures quite distinct from colorectal cancer, confirming their unique biology. Consequently, therapy for appendiceal lesions extrapolated from colonic cancer regimens may be unfounded. These phenotypes may predict outcomes guiding patient management.